drugset
drugset / Trial / NCT05611281

GS3-007a Oral Solution in Healthy Subjects

NCT05611281 ↗

Phase 1 Completed 96 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

To evaluate the safety and tolerability of GS3-007A in single, multiple, and single oral administration after high-fat meals in Chinese healthy adults.

Timeline

Start
2022-09-22
Primary completion
2023-04-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GS3-007 Unknown 0.4 mg/kg Oral
Subject GS3-007 Unknown 0.8 mg/kg Oral
Subject GS3-007 Unknown 1.6 mg/kg Oral
Subject GS3-007 Unknown 3.2 mg/kg Oral
Subject GS3-007 Unknown 4.8 mg/kg Oral
Subject GS3-007 Unknown 6.4 mg/kg Oral

Indications

No indication recorded.